The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19) (PROMISE)
The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19): (Randomized Clinical Trial)
There is an urgent need to explore therapeutic options for SARS-CoV-2 in order to face the pandemic. The selected intervention was based on that zafirlukast will have dual effect; first it will block the virus replication through inhibiting the COVID19 helicase that is involved in virus replication and secondly by reducing the inflammation through antagonizing the leukotriene receptor.
The purpose of this study is to evaluate the clinical efficacy and safety of Leukotriene receptor antagonist in the treatment of moderate cases of COVID-19 patients.
研究概览
研究类型
注册 (预期的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Riyadh、沙特阿拉伯、11426
- 招聘中
- King Abdulaziz Medical city, MNGHA
-
接触:
- Mohammed Al Ghobain, MD
- 电话号码:14219 009668011111
- 邮箱:alghobainmo@NGHA.MED.SA
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age of 18 years or above
- Diagnosed with COVID-19 by PCR confirmed SARS-coV-2 viral infection.
- Able to sign the consent form and agree to clinical samples collection
- Moderate symptomatic COVID-19 patients, (any or all of the followings: fever or cough or SOB)
- Admitted to the hospital (outside the ICU)
- Patients had to be enrolled within 10 days of symptoms onset.
- willingness to comply with all study procedures and availability for the duration of the study
Exclusion Criteria:
- Asthmatic patient using antiasthma medications
- Being in the hospital or in home isolation for more than 72 hours before the start of the study drug.
- Known sensitivity/allergy to the study drug
- Pregnancy
- Patient refused
- Chronic liver disease
- Severe mental disorder
- Unstable patients requiring ICU admission
- Participating in other clinical trial
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Treatment
Zafirlukast plus the standard treatment according to Saudi CDC protocol (combination experimental arm) Description of investigational drug Zafirlukast is leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. It is available as a tablet and is usually dosed twice daily. It is approved by USFDA and currently commercially marketed under the name of Accolate 20 mg oral tablet. The drug will be acquired from the pharmacy and will be received by the patient during the hospital admission via research coordinator. The study drug will be stored in at room temperature (15 - 25 c) in the hospital's pharmacy and a delegated pharmacist will be responsible for dispensing and return of any drugs. The study drug will be administrated to the patient in the dose of 20 mg orally twice daily for 10 days (fixed dose with no staring or escalating dose). |
Zafirlukast
|
安慰剂比较:Control
placebo plus the standard treatment according to Saudi CDC protocol
|
安慰剂
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Time to clinical improvement,
大体时间:28Day
|
The time from symptoms resolved: No fever for 72 hours, no cough, no SOB or live discharge from the hospital, whichever came first.
|
28Day
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Escalate therapy.
大体时间:28Day
|
The requirement to escalate therapy.
|
28Day
|
PCR test
大体时间:Day14
|
PCR test negative conversion rate at day 14
|
Day14
|
Length of hospital stay.
大体时间:28Day
|
Length of hospital stay.
|
28Day
|
Duration of fever
大体时间:28Day
|
Duration of fever
|
28Day
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Moderate Covid19的临床试验
-
Associazione Chirurghi Ospedalieri Italiani完全的
-
Abderrahmane Mami HospitalDacima Consulting; Eshmoun Clinical Research Center撤销
-
Texas Woman's UniversityNational Institutes of Health (NIH)尚未招聘COVID19测试
-
Aarhus University HospitalUniversity of Aarhus; Pharma Nord完全的
安慰剂的临床试验
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动,不招人造血和淋巴细胞肿瘤 | 骨髓纤维化 | 慢性淋巴细胞白血病 | 缓解期成人急性髓性白血病 | 骨髓增生异常综合症 | 缓解期成人急性淋巴细胞白血病 | 骨髓增殖性肿瘤 | 慢性期慢性粒细胞白血病,BCR-ABL1 阳性 | 成人淋巴母细胞淋巴瘤 | 加速期慢性粒细胞白血病,BCR-ABL1 阳性 | HLA-A*0201 阳性细胞存在 | 巨细胞病毒感染 | 成人霍奇金淋巴瘤 | 成人非霍奇金淋巴瘤美国
-
Mila (bMotion Technologies)完全的
-
Universidad Autonoma de MadridCentro Universitario La Salle完全的